Black Diamond Therapeutics Inc (BDTX)vsVertex Pharmaceuticals Inc (VRTX)
BDTX
Black Diamond Therapeutics Inc
$2.14
-0.47%
HEALTHCARE · Cap: $120.22M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 17045% more annual revenue ($12.00B vs $70.00M). VRTX leads profitability with a 32.9% profit margin vs 32.0%. BDTX trades at a lower P/E of 5.7x. VRTX earns a higher WallStSmart Score of 66/100 (B-).
BDTX
Buy63
out of 100
Grade: C+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.9%
Fair Value
$2.52
Current Price
$2.14
$0.38 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 32 of every $100 in revenue as profit
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 28.4%
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BDTX
The strongest argument for BDTX centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 32.0% and operating margin at 28.4%.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : BDTX
The primary concerns for BDTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BDTX profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
BDTX carries more volatility with a beta of 3.43 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 63/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Black Diamond Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?